Purpose: To assess the efficacy, safety, and follow-up of 36-month treatment with ranibizumab in patients with diabetic macular edema (DME) in real-life setting. Methods: This is a prospective phase 4 observational study. Between December 2013 and April 2015, 84 ophthalmologists enrolled a total of 290 adult patients initiating ranibizumab for visual impairment due to DME and treated them according to their routine practice. The primary outcome (mean change in best-corrected visual acuity [BCVA] after 12 months) was previously reported. Here, we present outcomes after 36 months of follow-up for BCVA and change in central subfield thickness (CSFT) and report how participating ophthalmologists treated DME over a 3-year period (number of visits and injections and evolution of treatment strategy). Results: Of the 290 patients enrolled, 187 (64.5%) completed the 36 months of the study (entire cohort). In the entire cohort, 97 patients were treated exclusively with ranibizumab throughout the study, and 90 patients switched to other intravitreal treatments. Mean BCVA was 64.2 (20.1) letters, representing a gain of +4.1 (19.9) letters from baseline to month 36 (M36). CSFT improved over the study, and by M36 had decreased by 127 (138) µm compared to baseline. Over the 36 months of follow-up, patients in the entire cohort paid their ophthalmologists a mean of 30.9 (12.2) visits and had a mean of 7.6 (5.2) any injections. Results for quality of life questionnaires NEI-VFQ25 and HUI-3 remained stable throughout the study. Multivariate analysis on the 145 patients with evaluable BCVA data at M36 found that male gender and milder baseline DME characteristics (BCVA ≥59 and CSFT <500 µm) were predictive factors for achieving a BCVA of ≥70 letters at M36. This study did not find any new safety signals, compared to the known profile of ranibizumab. Conclusions: Gains in BCVA in this real-life study were lower than those observed in randomized clinical trials with ranibizumab, mainly due to undertreatment. Safety analysis of ranibizumab did not yield any new safety concerns.

1.
Klein
R
,
Lee
KE
,
Gangnon
RE
,
Klein
BE
.
The 25-year incidence of visual impairment in type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy
.
Ophthalmology
.
2010
;
117
(
1
):
63
70
. .
2.
Moss
SE
,
Klein
R
,
Klein
BE
.
Ten-year incidence of visual loss in a diabetic population
.
Ophthalmology
.
1994
;
101
(
6
):
1061
70
. .
3.
Yau
JW
,
Rogers
SL
,
Kawasaki
R
,
Lamoureux
EL
,
Kowalski
JW
,
Bek
T
,
Global prevalence and major risk factors of diabetic retinopathy
.
Diabetes Care
.
2012
;
35
(
3
):
556
64
. .
4.
Massin
P
,
Bandello
F
,
Garweg
JG
,
Hansen
LL
,
Harding
SP
,
Larsen
M
,
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study
.
Diabetes Care
.
2010
;
33
(
11
):
2399
405
. .
5.
Nguyen
QD
,
Shah
SM
,
Khwaja
AA
,
Channa
R
,
Hatef
E
,
Do
DV
,
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
.
Ophthalmology
.
2010
;
117
(
11
):
2146
51
. .
6.
Mitchell
P
,
Bandello
F
,
Schmidt-Erfurth
U
,
Lang
GE
,
Massin
P
,
Schlingemann
RO
,
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
.
Ophthalmology
.
2011
;
118
(
4
):
615
25
. .
7.
Nguyen
QD
,
Brown
DM
,
Marcus
DM
,
Boyer
DS
,
Patel
S
,
Feiner
L
,
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE
.
Ophthalmology
.
2012
;
119
(
4
):
789
801
. .
8.
Massin
P
,
Creuzot-Garcher
C
,
Kodjikian
L
,
Girmens
JF
,
Delcourt
C
,
Fajnkuchen
F
,
Real-world outcomes with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study
.
Ophthalmic Res
.
2019
;
62
(
2
):
101
10
. .
9.
Eichenbaum
DA
,
Duerr
E
,
Patel
HR
,
Pollack
SM
.
Monthly versus treat-and-extend ranibizumab for diabetic macular edema: a prospective, randomized trial
.
Ophthalmic Surg Lasers Imaging Retina
.
2018
;
49
(
11
):
e191
7
. .
10.
Creuzot-Garcher
C
,
Massin
P
. Œdèmes maculaires (Société Française d’Ophtalmologie).
2016
.
11.
Best
AL
,
Fajnkuchen
F
,
Nghiem-Buffet
S
,
Grenet
T
,
Quentel
G
,
Delahaye-Mazza
C
,
Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting
.
J Ophthalmol
.
2018
;
2018
:
4610129
. .
12.
James
DGP
,
Mitkute
D
,
Porter
G
,
Vayalambrone
D
.
Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro re nata protocol from baseline: a real-world experience
.
Asia Pac J Ophthalmol
.
2019
;
8
(
3
):
200
5
.
13.
Epstein
D
,
Amren
U
.
Long-time outcome in patients treated with ranibizumab for diabetic macular edema: a 4-year study
.
Retina
.
2018
;
38
(
1
):
183
6
.
14.
Ziemssen
F
,
Wachtlin
J
,
Wachtlin
J
,
Kuehlewein
L
,
Gamulescu
M-A
,
Bertelmann
T
,
Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, multicenter study in Germany
.
Diabetes Ther
.
2018
;
9
(
6
):
2271
89
. .
15.
Egan
C
,
Zhu
H
,
Lee
A
,
Sim
D
,
Mitry
D
,
Bailey
C
,
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema
.
Br J Ophthalmol
.
2017
;
101
(
1
):
75
80
. .
16.
Adelman
R
,
Parnes
A
,
Michalewska
Z
,
Parolini
B
,
Boscher
C
,
Ducournau
D
.
Strategy for the management of diabetic macular edema: the European Vitreo-Retinal Society Macular Edema Study
.
Biomed Res Int
.
2015
;
2015
:
352487
. .
17.
Weiss
M
,
Sim
DA
,
Herold
T
,
Schumann
RG
,
Liegl
R
,
Kern
C
,
Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice
.
Retina
.
2018
;
38
(
12
):
2293
300
.
18.
Chen
YP
,
Wu
AL
,
Chuang
CC
,
Chen
SN
.
Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases
.
Sci Rep
.
2019
;
9
(
1
):
10952
. .
19.
Sophie
R
,
Lu
N
,
Campochiaro
PA
.
Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab
.
Ophthalmology
.
2015
;
122
(
7
):
1395
401
. .
20.
Shimura
M
,
Kitano
S
,
Muramatsu
D
,
Fukushima
H
,
Takamura
Y
,
Matsumoto
M
,
Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study
.
Br J Ophthalmol
.
2020
;
104
(
9
):
1209
15
.
21.
Stefanickova
J
,
Cunha-Vaz
J
,
Ulbig
M
,
Pearce
I
,
Fernández-Vega Sanz
A
,
Theodossiadis
P
,
A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)
.
Acta Ophthalmol
.
2018
;
96
(
8
):
e942
e9
. .
22.
Ziemssen
F
,
Feltgen
N
,
Holz
FG
,
Guthoff
R
,
Ringwald
A
,
Bertelmann
T
,
Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials
.
BMC Ophthalmol
.
2017
;
17
(
1
):
7
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.